US Markets for Alzheimer's Disease Medications

Published by: Millennium Research

Published: Apr. 1, 2005

Table of Contents

EXECUTIVE SUMMARY

METHODOLOGY

1.0 AD OVERVIEW

1.1 Definition of AD

1.1.1 Symptoms

1.1.2 Diagnosis

1.2 Segmentation of AD

1.3 Prevalence of AD

1.4 Unmet Needs in AD

1.5 Market Analyses Assumptions

1.5.1 Generic Competition

1.5.2 Mild to Moderate Market Assumptions

1.5.3 Moderate to Severe Market Assumptions

1.6 Market Analysis

1.6.1 Market Forecast

1.7 Drugs That Address Associated Conditions

1.8 AD Research and Development

1.8.1 ACh Modulators

1.8.2 Neuroprotective and Neurotrophic Drugs

1.8.3 Beta-Amyloid Modulators

1.8.4 Beta-Secretase Inhibitors

1.8.5 Other Compounds Under Development for AD

1.8.6 Application of Existing Products to AD

1.8.7 Innovative Approaches

1.9 Competitive Analysis

2.0 AD PATIENT POPULATION

2.1 Definition of AD

2.1.1 Epidemiology

2.1.1.1 Clinical Investigations

2.1.2 Symptoms

2.1.3 Diagnosis

2.1.3.1 Psychological Testing

2.2 Segmentation of AD

2.2.1 Mild to Moderate Forms of AD

2.2.1.1 Mild Cognitive Impairment

2.2.2 Moderate to Severe Forms of AD

2.3 AD Prevalence

2.3.1 Mild to Moderate AD Prevalence

2.3.2 Moderate to Severe AD Prevalence

2.4 Treated AD Patients

2.5 Average Selling Prices

2.6 Unmet Needs in Diagnosis and Treatment of AD

2.6.1 US Health Care Structure

2.6.2 Issues Specific to AD Patients

3.0 MILD TO MODERATE AD MARKET

3.1 Market Overview

3.2 Mild to Moderate AD Drugs

3.2.1 Cognex

3.2.1.1 Cognex Clinical Results

3.2.1.2 Cognex Formulation, Dosing, and Compliance

3.2.2 Aricept

3.2.2.1 Aricept Clinical Results

3.2.2.1.2 Aricept Side Effects

3.2.2.2 Aricept Formulation, Dosing, and Compliance

3.2.3 Exelon

3.2.3.1 Exelon Clinical Results

3.2.3.2 Exelon Formulation, Dosing, and Compliance

3.2.4 Reminyl

3.2.4.1 Reminyl Clinical Results

3.2.4.2 Reminyl Formulation, Dosing, and Compliance

3.3 Market Analysis

3.4 Competitive Analysis

4.0 MODERATE TO SEVERE AD MARKET

4.1 Market Overview

4.2 Moderate to Severe AD Drugs

4.2.1 Namenda

4.2.1.1 Namenda Clinical Results

4.2.1.2 Namenda Formulation, Dosing, and Compliance

4.3 Market Analysis

4.4 Competitive Analysis

5.0 RESEARCH AND DEVELOPMENT

5.1 AD Research Overview

5.1.1 ACh Modulators

5.1.1.1 ACh Modulators Drug Overview

5.1.1.2 ACh Modulators Drug Clinical Trial Data

5.1.1.3 ACh Modulators Drug Candidates by Clinical Stage

5.1.2 Neuroprotective and Neurotrophic Drugs

5.1.2.1 Neuroprotective and Neurotrophic Drug Overview

5.1.2.2 Neuroprotective and Neurotrophic Drug Clinical Trial Data

5.1.2.3 Neuroprotective and Neurotrophic Drug Candidates by Clinical Stage

5.1.3 Beta-Amyloid Modulators

5.1.3.1 Beta-Amyloid Modulators Overview

5.1.3.2 Beta-Amyloid Modulators Clinical Trial Data

5.1.3.3 Beta-Amyloid Modulator Drug Candidates by Clinical Stage

5.1.4 Beta-Secretase Inhibitors

5.1.4.1 Beta-Secretase Inhibitor Drug Overview

5.1.4.2 Beta-secretase Inhibitor Clinical Trial Data

5.1.4.3 Beta-Secretase Inhibitor Drug Candidates by Clinical Stage

5.1.5 Other Drugs Under Development for AD

5.1.5.1 N-methyl-D-aspartate Receptor Antagonists

5.1.5.2 Phospholipid-Based Drugs

5.1.5.3 L-Type Calcium Channel Modulators

5.1.5.4 PDE-4 Compounds

5.1.5.5 Ampakine Compounds

5.1.5.6 Protein Deposition Inhibitors Overview

5.1.6 Application of Existing Products to AD

5.1.6.1 Statins

5.1.6.2 Antioxidants

5.1.6.3 Hormones

5.1.6.4 Lithium

5.1.6.5 Rosiglitazone

5.1.6.6 Nonsteroidal Anti-Inflammatory Drugs

5.1.6.7 Anti-Hypertensives

5.1.6.8 Rasagilene

5.1.6.9 HT Agonists

5.1.6.10 Valproate

5.1.7 Innovative Approaches

5.1.7.1 Gene Therapy

5.1.7.2 Vaccines

5.2 Companies Involved in AD Research

5.2.1 Eli Lilly

5.2.2 Pfizer/Eisai

5.2.3 Sanofi-Aventis

5.2.4 Axonyx

5.2.5 Nymox

5.2.6 Prana Biotechnology

5.2.7 Neurochem

5.3 Discontinued Development Projects

5.3.1 ProMem—Bayer

5.3.2 Viviq—Aventis

APPENDIX A: MRG ACRONYMS AND INITIALISMS

List of Exhibits

EXECUTIVE SUMMARY

Exhibit ES-1: AD Drug Market, by Region, Global, (US$), 2003-2009

Exhibit ES-2: AD Prevalence Rates, by Region and Disease Stage, Global, 2004. ES-3

Exhibit ES-3: Treated AD Patients, by Region, Global, 2003-2009

Exhibit ES-4: ASP per Patient, by Region, Global, (US$), 2003-2009

Exhibit ES-5: Mild to Moderate AD Drug Market, by Brand, Global, (US$), 2003-2009

Exhibit ES-6: Memantine Marketing Rights, by Region, Brand, and Company, Global, 2004

Exhibit ES-7: Moderate to Severe AD Drug Market, as a % of Total, by Region, Europe, 2004 versus 2009

Exhibit ES-8: Leading Competitors in the AD Drug Market, Global, 2004

CHAPTER 1: AD OVERVIEW

Exhibit 1-1: AD Prevalence Rates, by Disease Stage, US, 2004

Exhibit 1-2: Availability of AD Drug Medications, US, Q1 2005

Exhibit 1-3: AD Drug Market, by Brand, US (US$), 2003-2009 (Tabular Format)

Exhibit 1-4: AD Drug Market, by Brand, US (US$), 2003-2009 (Graphical Format)

Exhibit 1-5: Leading Competitors in the AD Drug Market, Market Value and Market Shares, (US$), US, 2004

CHAPTER 2: AD PATIENT POPULATION

Exhibit 2-1: GDS AD Classification Framework

Exhibit 2-2: AD Prevalence, by Disease Stage, US, 2004

Exhibit 2-3: AD Prevalence Rate, US, 2004

Exhibit 2-4: AD Prevalence, by Disease Stage, US, 2003-2009 (Tabular Format)

Exhibit 2-5: AD Prevalence, by Disease Stage, US, 2003-2009 (Graphical Format).34

Exhibit 2-6: Treated AD Patients, US, 2003-2009 (Tabular Format)

Exhibit 2-7: Treated AD Patients, US, 2003-2009 (Graphical Format)

Exhibit 2-8: ASP per Patient, US (US$), 2003-2009 (Tabular Format)

Exhibit 2-9: ASP per Patient, US (US$), 2003-2009 (Graphical Format)

CHAPTER 3: MILD TO MODERATE AD MARKET

Exhibit 3-1: Mild to Moderate AD Drug Market, US (US$), 2003-2009

Exhibit 3-2: Availability of Mild to Moderate AD Drugs, by Brand, Global, 2004

Exhibit 3-3: Selected New Mild to Moderate AD Medications, US, 2003-2009

Exhibit 3-4: Mild to Moderate AD Drug Market, by Brand, US (US$), 2003-2009 (Tabular Format)

Exhibit 3-5: Mild to Moderate AD Drug Market, by Brand, US (US$), 2003-2009 (Graphical Format)

Exhibit 3-6: Leading Competitors in the Mild to Moderate AD Drug Market, US, 2004

Exhibit 3-7: Leading Competitors in the Mild to Moderate AD Drug Market, US, 2004

CHAPTER 4: MODERATE TO SEVERE AD MARKET

Exhibit 4-1: Moderate to Severe AD Drug Market, US, (US$), 2003-2009

Exhibit 4-2: Anticipated Medications for Treatment of Moderate to Severe AD, US, 2003-2009

Exhibit 4-3: Moderate to Severe AD Drug Market, by Brand, US (US$), 2003-2009 (Tabular Format)

Exhibit 4-4: Moderate to Severe AD Drug Market, by Brand, US (US$), 2003-2009 (Graphical Format)

CHAPTER 5: RESEARCH AND DEVELOPMENT

Exhibit 5-1: Selected New AD Drug Candidates, by Clinical Stage, Q4 2004

Exhibit 5-2: Selected ACh Modulators Drug Candidates, by Clinical Stage, Q4 2004

Exhibit 5-3: Selected Neuroprotective and Neurotrophic Drug Candidates, by Clinical Stage, Q4 2004

Exhibit 5-4: Selected Beta Amyloid Modulators Drug Candidates, by Clinical Stage, Q4 2004

Exhibit 5-5: Selected BACE Inhibitor Drug Candidates, by Clinical Stage, Q4 2004

Abstract

About MarketResearch.com
MarketResearch.com is an online aggregator selling over 250,000 market research reports, company profiles and country profiles from over 650 research firms. Our reports will provide you with the critical business and competitive intelligence you need for strategic planning and marketing research. Coverage includes the US, UK, Europe, Asia and global markets.